Engineered IL‐21‐Expressing Nanovesicles for Co‐Delivery of GOX and Ferrocene to Induce Synergistic Anti‐Tumor Effects
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202403477 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Chao Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Anhui Medical University, Hefei, Anhui, 230032, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Ferrous Compounds, Glucose Oxidase, Interleukin-21. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Research Fund of Anhui Institute of Translational Medicine, Scientific Research of BSKY from Anhui Medical University, the University Natural Science Research Project of Anhui Province.
Abstract (Originalsprache)
Glucose oxidase (GOX)‐induced starvation is a safe treatment for tumor. However, the non‐specific targeting of GOX and the plasticity of tumor metabolism lead to toxic side effects and low tumor mortality. Thus, it is necessary to develop a synergistic strategy with high tumor targeting specificity to enhance the mortality of GOX. In this study, a genetically engineered CD44 targeting peptide (CP) and IL‐21 fusion protein‐displaying nanovesicles platform (mCP@IL21‐Fc‐GOX) are designed to efficiently encapsulate GOX and ferrocene (Fc). After reaching the tumor site, IL‐21 can be precisely released and targeted to NK cells through the cleavage of MMP‐2, thus achieving precise anti‐tumor immunotherapy of IL‐21. Second, the exposed CP enable mCP‐Fc‐GOX to be further targeted to tumor cells, completing the synergistic anti‐cancer effects of starvation and chemodynamic therapy (CDT) triggered by GOX and Fc. In situ breast cancer models, the results show that mCP@IL21‐Fc‐GOX not only enhances NK and T cells aggregation in tumor tissue but also achieves precise nutrition deprivation and abundant reactive oxygen species production, thus significantly inhibits tumor growth based on the synergistic function of the immunotherapy, starvation and CDT. Therefore, this work provides a smart nanovesicle platform for achieving precise and safe synergistic anti‐tumor therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Sciences, Anhui Medical University, Hefei, Anhui, 230032, China.
ORCID-Profile: Lin Huang
Förderung
- Research Fund of Anhui Institute of Translational Medicine
- Scientific Research of BSKY from Anhui Medical University
- the University Natural Science Research Project of Anhui Province
- the National Natural Science Foundation of China
Zitieren
APA
Li, C., Zhou, M., Li, Y., Jia, H., & Huang, L. (2025). Engineered IL‐21‐Expressing Nanovesicles for Co‐Delivery of GOX and Ferrocene to Induce Synergistic Anti‐Tumor Effects. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202403477
Vancouver
Li C, Zhou M, Li Y, Jia H, Huang L. Engineered IL‐21‐Expressing Nanovesicles for Co‐Delivery of GOX and Ferrocene to Induce Synergistic Anti‐Tumor Effects. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202403477
BibTeX
@article{Li2025,
author = {Li, Chao and Zhou, Mengyang and Li, Yang and Jia, Haojie and Huang, Lin},
title = {Engineered IL‐21‐Expressing Nanovesicles for Co‐Delivery of GOX and Ferrocene to Induce Synergistic Anti‐Tumor Effects},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202403477}
}
EUVIMED